Panels find FDA, Biogen rushed Alzheimer's drug
The biotechnology company Biogen and its regulator, the Food and Drug Administration, worked in concert -- ignoring internal concerns from the company and skirting the agency's own written guidance -- to allow the Alzheimer's treatment Aduhelm to receive accelerated approval and hit the market at a cost to patients of $56,000 annually, according to a report released Thursday by two House committees.